These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 7159742

  • 1. Reduction of iron overload in thalassemia.
    Piomelli S, Graziano J.
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract] [Full Text] [Related]

  • 2. Clinical management of beta-thalassemia.
    Graziano J, Piomelli S.
    Tex Rep Biol Med; 1982; 40():355-64. PubMed ID: 7034276
    [No Abstract] [Full Text] [Related]

  • 3. Iron chelating therapy in thalassemia: current problems.
    Russo G.
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract] [Full Text] [Related]

  • 4. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B.
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract] [Full Text] [Related]

  • 5. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM, Hoffbrand AV, Politis D.
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract] [Full Text] [Related]

  • 7. The treatment of Cooley's anemia.
    Nathan DG.
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of iron overload in Cooley's anemia.
    Cohen A, Mizanin J, Schwartz E.
    Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
    [No Abstract] [Full Text] [Related]

  • 9. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E, Baronciani D, Lucarelli G, Giardini C, Galimberti M, Polchi P, Martinelli F, Baldassarri M, Muretto P.
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract] [Full Text] [Related]

  • 10. Medical management of beta-thalassemia.
    Lerner N.
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract] [Full Text] [Related]

  • 11. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA, Barry M, Flynn DM.
    J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
    [Abstract] [Full Text] [Related]

  • 12. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS, Sanchis de Herrlein MS, Peñalver JA.
    Medicina (B Aires); 1985 Jun; 45(3):231-4. PubMed ID: 3841934
    [No Abstract] [Full Text] [Related]

  • 13. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD, Shurin SB, Nathan DG.
    N Engl J Med; 1976 Jun 24; 294(26):1421-3. PubMed ID: 1272274
    [Abstract] [Full Text] [Related]

  • 14. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S.
    Acta Haematol; 1982 Jun 24; 68(2):115-23. PubMed ID: 6812366
    [Abstract] [Full Text] [Related]

  • 15. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 24; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 16. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M, Karpatkin M, Hart D, Seaman C, Vora SK, Henry WL, Piomelli S.
    J Pediatr; 1978 Apr 24; 92(4):653-8. PubMed ID: 633033
    [No Abstract] [Full Text] [Related]

  • 17. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M, Galdo Capotorti M, Ponte G, Esposito L.
    Pediatria (Napoli); 1983 Apr 24; 91(4):371-7. PubMed ID: 6545400
    [No Abstract] [Full Text] [Related]

  • 18. Beta-thalassaemia--the Johannesburg experience.
    Poole JE, Cohn RJ, Roode H, Spector I.
    S Afr Med J; 1989 Apr 15; 75(8):367-70. PubMed ID: 2652340
    [Abstract] [Full Text] [Related]

  • 19. Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major.
    De Virgiliis S, Argiolu F, Rais M, Cossu P, Toccafondi C, Sanna G, Cornacchia G, Nucaro A, Ferreli A, Cao A.
    Birth Defects Orig Artic Ser; 1982 Apr 15; 18(7):355-60. PubMed ID: 6819018
    [No Abstract] [Full Text] [Related]

  • 20. [Use of desferrioxamine B in the treatment of post-transfusion hypersiderosis].
    Orsini A, Giraud F, Bernard P, Passeron P.
    Mars Med; 1965 Apr 15; 102(7):591-5. PubMed ID: 5855127
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.